Editorial Board member, Bernardo Rapoport discusses neoadjuvant breast cancer at the ASCO 2019 annual meeting. Considering data presented at the meeting he also reviews the unmet needs, what factors influence treatment in this population and how to overcome current treatment challenges.
1. What are the major unmet needs in the neoadjuvant treatment of breast cancer? (0:04)
2. What factors influence the decision to give neoadjuvant treatment? (2:20)
3. What are the challenges of assessing response to neoadjuvant therapies and how can these be overcome? (3:06)
4. Could you tell us about the latest data on trastuzumab emtansine in the neoadjuvant treatment of HER2-positive breast cancer? (4:08)
5. What presentations on neoadjuvant breast cancer are you most interested in at this year’s meeting? (5:59)
Speaker disclosure: Bernardo Rapoport has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Breast Cancer
Javier Cortés, ESMO 2021: Results of the Randomized Phase III DESTINY-Breast03 Study
touchONCOLOGY joins Dr Javier Cortés at ESMO 2021 to discuss the much-anticipated results of the randomized phase III DESTINY-Breast03 study. Questions 1. Why are antibody-drug conjugates needed in the treatment of HER2+ metastatic breast cancer? (00:17-01:17) 2. What were the objectives of the phase III DESTINY-Breast03 study? (01:17-01:55) 3. Could you tell us a little […]
Sara Tolaney, ASCO 2021: Abemaciclib in HR+, HER2+ high-risk early breast cancer
touchONCOLOGY joins Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) at ASCO 2021 to discuss unmet needs and ongoing research in patients with early-stage HER2+ breast cancer. The abstract ‘eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer […]
Sara Tolaney, St. Gallen International Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE
Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!